| Breakdown | Dec 2025 | Dec 2023 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 258.00M | 241.00M | 220.00M | 227.00M | 197.00M |
| Gross Profit | 213.00M | 170.00M | 172.00M | 178.00M | 146.00M |
| EBITDA | -4.67B | 5.74B | 4.75B | -9.23B | 6.36B |
| Net Income | -4.68B | 5.74B | 4.75B | -9.24B | 6.35B |
Balance Sheet | |||||
| Total Assets | 20.09B | 24.74B | 19.19B | 14.64B | 24.00B |
| Cash, Cash Equivalents and Short-Term Investments | 342.00M | 782.00M | 1.58B | 532.00M | 459.00M |
| Total Debt | 254.00M | 3.00M | 3.00M | 3.00M | 4.00M |
| Total Liabilities | 270.00M | 52.00M | 57.00M | 95.00M | 48.00M |
| Stockholders Equity | 19.81B | 24.68B | 19.12B | 14.54B | 23.94B |
Cash Flow | |||||
| Free Cash Flow | 0.00 | 172.00M | 1.37B | 160.00M | 958.00M |
| Operating Cash Flow | 296.00M | 172.00M | 1.37B | 176.00M | 980.00M |
| Investing Cash Flow | -748.00M | -778.00M | -124.00M | 39.00M | -1.67B |
| Financing Cash Flow | 47.00M | -201.00M | -206.00M | -125.00M | -151.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
64 Neutral | kr7.38B | 33.37 | 15.16% | ― | 11.30% | -14.49% | |
63 Neutral | kr9.36B | 7.72 | 12.47% | 2.18% | 4.72% | -38.28% | |
56 Neutral | kr12.35B | -17.98 | 6.59% | 3.70% | -22.65% | -14.05% | |
53 Neutral | kr15.90B | -3.40 | -23.18% | 1.13% | 22.38% | -153.85% | |
46 Neutral | kr17.77B | -5.28 | 0.33% | ― | -97.64% | ― | |
45 Neutral | kr17.77B | -5.79 | ― | ― | -97.64% | ― |
Bure Equity AB reported a sharp deterioration in 2025, with net asset value per share falling 19.8% to SEK 267.2 and total shareholder return at -34.8%, significantly underperforming the SIX Return Index. Group earnings swung to a loss of SEK 4,676M, driven mainly by steep share price declines in key portfolio holdings such as Yubico, Xvivo, and Vitrolife, whose growth and profitability lagged market expectations.
Operational performance across the portfolio was mixed: Mycronic delivered strong growth and profit, while Vitrolife, Yubico, and Xvivo faced weaker demand and margin pressure. Bure reshaped its portfolio by acquiring a 17% stake in MEMS foundry leader Silex Microsystems for SEK 900M and funding this partly through divestments in Ovzon, Mycronic, and the full exit from Mentice, while also subscribing to BioLamina convertibles and continuing to fine-tune holdings.
After the balance sheet date, net asset value per share declined further to SEK 233.0 by 18 February 2026, even as Bure continued to sell down Ovzon and proposed maintaining an ordinary dividend of SEK 2.75 per share. CEO Henrik Blomquist highlighted a tough market environment marked by currency headwinds, revaluation of growth stocks, and geopolitical uncertainty, but reaffirmed confidence in the portfolio’s long-term quality and emphasised near-term focus on improving profitability and positioning for future growth.
The most recent analyst rating on (SE:BURE) stock is a Hold with a SEK215.00 price target. To see the full list of analyst forecasts on Bure Equity AB stock, see the SE:BURE Stock Forecast page.
Bure Equity AB reported a difficult 2025, with net asset value per share falling 19.8% to SEK 267.2 and group earnings after tax swinging to a loss of SEK 4.7 billion, sharply underperforming the broader Swedish market. Weak share price performance in several key portfolio companies, notably Yubico, Xvivo and Vitrolife, offset strong results from Mycronic, while management intensified portfolio rebalancing through divestments in Ovzon and Mentice and a major SEK 900 million investment in MEMS foundry leader Silex Microsystems, signalling a continued long-term commitment to technology assets despite a challenging market and early 2026 NAV declines.
The CEO highlighted that Bure’s concentration in growth technology stocks, combined with a stronger Swedish krona and missed growth expectations in some holdings, drove severe valuation compressions and a negative total shareholder return of 34.8%. At the same time, the group emphasized operational improvements in select unlisted assets such as Mentimeter, strategic shifts in geographic exposure like Vitrolife’s gains in North America, and a belief that enhancing profitability across portfolio companies is key to restoring growth and supporting stakeholders amid ongoing macroeconomic and geopolitical uncertainty.
The most recent analyst rating on (SE:BURE) stock is a Hold with a SEK215.00 price target. To see the full list of analyst forecasts on Bure Equity AB stock, see the SE:BURE Stock Forecast page.
Bure Equity AB has signed an agreement to divest 4,037,824 shares in Mentice AB to Gulf Offshore Limited, a company controlled by the Howell family, which is the main owner of Mentice. Following this transaction, Bure will retain 100,000 shares in Mentice, which secures its issued call options, potentially impacting its strategic positioning and financial interests in the company.
The most recent analyst rating on (SE:BURE) stock is a Hold with a SEK261.00 price target. To see the full list of analyst forecasts on Bure Equity AB stock, see the SE:BURE Stock Forecast page.
Bure Equity AB has announced an increase in its total number of shares and votes, following the issuance and immediate repurchase of 144,562 C shares under its LTIP 2025 incentive program. This change reflects a strategic move to adjust its share capital and voting rights, with the total number of shares now at 74,646,317 and votes at 74,240,396, potentially impacting shareholder value and company governance.
The most recent analyst rating on (SE:BURE) stock is a Hold with a SEK261.00 price target. To see the full list of analyst forecasts on Bure Equity AB stock, see the SE:BURE Stock Forecast page.